Soft Tissue Defects
2
Pipeline Programs
1
Companies
2
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Aroa BiosurgeryNew Zealand - Auckland
2 programs2
Myriad MatrixPhase 41 trial
Myriad™ applied in conjunction with NPWTPhase 41 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
2028
2029
Aroa BiosurgeryMyriad™ applied in conjunction with NPWT
Aroa BiosurgeryMyriad Matrix
Clinical Trials (2)
Total enrollment: 830 patients across 2 trials
Combined OFM and Vacuum-assisted Therapy for Expedited Regeneration Over Structures
Start: Mar 2026Est. completion: Apr 202730 patients
Phase 4Recruiting
Myriad™ Augmented Soft Tissue Reconstruction Registry
Start: Jan 2022Est. completion: Jan 2029800 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 830 patients
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.